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TuberculosisA B S T R A C T
Objective/background: The World Health Organization (WHO) declared tuberculosis (TB) as a
global public health emergency and recommended directly observed treatment, short-
course (DOTS) as a standard strategy to control the disease. In Ethiopia the strategy was
started in 1992 as a pilot in the Arsi and Bale zone, Oromia Region. The DOTS strategy
has been subsequently scaled up in the country and implemented at a national level reach-
ing better coverage, although there are recognizable variations from region to region and
district to district. The aim of this study was to assess the impact of the DOTS strategy
on smear-positive pulmonary TB case findings and their treatment outcomes in the Afar
Regional State, Ethiopia, from 2003 to 2012 and from 2002 to 2011, respectively.
Methods: A health facility-based retrospective study was conducted. Data were collected
and reported on a quarterly basis using the WHO reporting format for TB case findings and
their treatment outcomes from all DOTS-implementing health facilities in all zones of the
region to the Federal Ministry of Health.
Results: A total of 34,894 of TB cases hadbeen registered in theperiod from2003 to 2012. Out
of these, 11,595 (33.2%) were smear-positive pulmonary TB, 13,859 (39.7%) smear-negative
pulmonary TB, and 9838 (28.2%) extrapulmonary TB. The case detection rate (CDR) of
smear-positive pulmonary TB had increased from 18.3% to 37.2%, with the average value
being 32% (standard deviation = 6.8) from the total TB cases to its peak of 39% in 2008. The
treatment success rate (TSR) had an average value of 86.2% from 2002 to 2011 with its peak
value being 96.5% in 2007.Moreover, the averagevalues of treatment defaulter and treatment
failure rate were 2.9% and 2.7%, respectively.93, Asella,
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smear-positive TB, although it is unacceptably lower than the recommended WHO target
of 70%. Additionally, theWHO target of 85% for TSR had already been achieved in the region.
However, continued efforts should be in place to increase the CDR andmaintain the highTSR
registered.
 2016 Production and hosting by Elsevier Ltd. on behalf of Asian African Society for
Mycobacteriology.Introduction to 2012 and for their treatment outcomes from 2002 to 2012 inTuberculosis (TB) is an infectious disease caused by Mycobac-
terium tuberculosis, which is a rod-shaped bacillus called
‘‘acid-fast” due to its staining characteristics in the laboratory.
Globally, in 2012, an estimated 8.6 million people developed
TB.At thesame time, therewere1.3milliondeaths fromthedis-
ease (including an estimated 1.1 million cases and 320,000
deaths among human immunodeficiency virus [HIV] infected
people). About 58% of the 8.6 million people who developed TB
in 2012 were from Asian and African Regions, respectively [1].
In 1993, the World Health Organization (WHO) declared TB
as a global public health emergency and recommended
directly observed treatment, short-course (DOTS) as a stan-
dard strategy to control TB. The multidimensional DOTS
framework was being implemented in 184 countries and over
132 million patients had been treated with DOTS which
resulted in more than 125 million people being cured [2].
The specific targets of DOTS were detailed in the updated glo-
bal plan of TB from 2011 to 2015 for achieving a case detection
rate (CDR) of 84% (for all forms of TB) and a treatment success
rate (TSR) of 87% for smear-positive TB by 2015 [3].
TheDOTSstrategywaspiloted inEthiopia in 2000at theArsi
and Bale zones of Oromia Regional State [4]. In 2010, it was
gradually scaled up to the entire country and came to have
100% district- and 90% health-facility coverage [5]. Evaluating
treatment outcome of TB is essential in order to assess the
effectiveness of DOTS strategy in different regions of a given
country [6]. Additionally, understanding the specific reasons
for unsuccessful treatment outcomes is helpful for improving
the quality and accessibility of treatment service [7]. The aim
of this study was to assess the impact of the DOTS strategy
on smear positive-pulmonary TB case findings and their treat-
ment outcomes in the Afar Regional State, Ethiopia from 2003
to 2012 and from 2002 to 2011, respectively.
Materials and methods
Study area
The Afar Regional State consists of five administrative zones
and 30 districts. The size of the population in the region
according to the 2007 National Census was about 1,390,273,
out of which 775,117 (55.75%) were men and 615,156
(44.25%) women [8].
Study design
Health facility-based retrospective data were collected for TB
cases that were registered during the study period from 2003the Afar Regional State.
Inclusion and exclusion criteria
All forms of TB cases that were registered during the study
period were included in the study. Treatment outcomes of
extrapulmonary TB and smear-negative pulmonary TB cases
were excluded as treatment outcomes mainly focus on
smear-positive pulmonary TB cases due to their infectious-
ness compared to other forms of TB and the scope of study.
Data collection procedures
Data were collected by WHO standardized reporting formats
for case detection and treatment outcomes. Reports from all
zones in the region were collected by trained data collectors
and investigators. Data were first collected from health facil-
ities where TB focal persons compiled the data and reported it
on a quarterly basis about all TB patients entered into the TB
clinic, assigned a unique TB registration number for each TB
patient, and submitted the report to zonal TB focal persons
who were responsible for compiling a zonal summary, and
in turn, the zonal TB focal persons submitted the report to
the regional TB Program Officer. The regional TB Program Offi-
cer checked the completeness, quality, and accuracy of the
reports. Then, data were analyzed and interpreted, and sent
as a compiled report to the Office of National Tuberculosis
and Leprosy Control Program Office, Federal Ministry of
Health.
Data analysis
Data that were collected and reported from standardized
WHO formats were analyzed and interpreted using excel
spread sheets and SPSS version 20 (SPSS Inc., Chicago, Il,
USA). Data were summarized using frequencies, percentages,
and standard deviations including for mean values of vari-
ables like CDR, TSR, death rate, and defaulter rate.
Data validation
Federal Ministry of Health (FMOH), Ethiopia used the Health
Management Information System for all health program
recording and reporting, which consisted of its own unique
data collection book and reporting format. Data that were
obtained by WHO reporting formats were crosschecked for
the data which were obtained in the Health Management
Information System for maintaining consistency of informa-
tion within the study period.
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CDR
Percentage of smear-positive TB cases detected among the
total number of TB cases estimated to occur.
Smear-positive pulmonary TB
A patient with at least two initial sputum smear positive for
acid-fast bacilli (AFB) with direct microscopy or a patient with
only one sputum smear positive for AFB and with chest radio-
graphic abnormalities consistent with active pulmonary TB
followed by the clinician’s decision.
Smear-negative pulmonary TB
A patient with at least three initial sputum smear negative for
AFB with direct microscopy and with chest radiographic
abnormalities consistent with active pulmonary TB and no
clinical response to 2 weeks of broad spectrum antibiotic
therapy followed by the clinician’s decision.
Extrapulmonary TB
TB involving organs other than the lungs, such as skin, abdo-
men, joints and bones, lymph nodes, pleura, genitourinary
tract, and meninges.
Treatment success rate
A sum of smear-positive TB cases who completed treatment
and who were declared cured divided by the total smear-
positive TB cases in the same period.
Defaulter
A patient who has been on treatment for at least 4 weeks and
whose treatment was interrupted for P8 consecutive weeks.
Transfer out
A patient who has started treatment and has been transferred
to another health facility and for whom treatment outcome is
not known at the time of evaluation.Cured
A patient who is sputum-smear negative 1 month prior to the
completion of treatment and on at least one previous occa-
sion (usually at the end of the 2nd month or 5th month).Treatment completed
A patient who has completed treatment but in whom smear
results are not available at or 1 month prior to the completion
of treatment.Treatment failure
A patient who remained smear positive or became smear pos-
itive again at the end of P5 months after commencing
treatment.Ethical considerations
The study secured ethical clearance from institutional review
board of afar regional stat health bureau.Results
A total of 34,894 cases were registered with all forms of TB for
the past 10 years (from 2003 to 2012; Table 1). Out of these,
11,595 (33.2%) were smear-positive pulmonary TB, 13,859
(39.7%) smear-negative pulmonary TB, and 9838 (28.2%) extra-
pulmonary TB (Table 1). Trends of case finding for all forms of
TB cases were shown for the decade (Fig. 1). CDR of smear-
positive TB had increased from 18.3% to 37.2% with an aver-
age value of 32% (standard deviation = 6.8) from the total TB
cases to its peak of 39% in 2008 (Fig. 3).
Out of 7345 smear-positive cases, the highest number of
cases (1233 [23.1%]) were reported among age group ranges
from 25 years to 34 years followed by 374 (7%) in the age group
of 15–24 years, while the lowest number of cases (25 [0.5%])
were reported among the age group P65 years (Table 2).
A total of 12,162 smear-positive TB patients were consid-
ered as a cohort for treatment outcome. Eleven thousand five
hundred and eighty-three (95.2%) of them were evaluated for
their treatment outcome from the period of 2002–2012
(Table 3). Among the total evaluated smear-positive TB cases,
4245 (34.9%) were cured and 5781 (47.5%) completed their
treatment which give a total value of TSR of 86.2%.
TSR had an average value of 86.2% from 2002 to 2011 with
its peak value being 96.5% in 2007 and then it significantly
declined in 2004 by 34.2% (Fig. 3). The targets by WHO for
TSR had already been achieved, as the TSR was >85% from
2006 onwards in the region. Among the total 12,162 smear-
positive TB patients who registered during 2002–2011, the
cure rate, death rate, failure rate, default rate, and transfer
out were found to be 4245 (34.9%), 272 (2.2%), 330 (2.7%), 353
(2.9%), and 381 (3.1%), respectively (Table 3 and Fig. 2).
Discussion
A total of 34,894 cases were registered with all forms of TB for
treatment. Of these, 11,595 (33.2%), 13,859 (39.7%), and 9838
(28.2%) were smear-positive TB, smear-negative TB, and
extrapulmonary TB, respectively. Smear-positive TB CDR
had increased from 18.3% to 37.2% from the total TB cases
registered for the study period. Similarly, trends of incre-
ments were recorded in the study done in the Gambella
region [9] and Addis Ababa City Administration [10]. The
increment in the case detection of smear-positive pulmonary
TB cases might be linked to the decentralization and expan-
sion of the DOTS program in the country. It might also be
explained by the influence of improvement of diagnostic set-
tings of health facilities in the region as per the National
Tuberculosis Control Program recommendation. However,
the total average value of CDR was 33.2% for the study period
which was by far less than the WHO target of 70%. The possi-
ble explanation might be because the CDR relies on an esti-
mate for the incidence of TB; therefore, it is difficult to
measure accurately in most settings, especially in the context
of a high prevalence of HIV [11]. Additionally, the national
average CDR for the year 2008 was 34% [12]. This might be
linked to inadequate decentralization of DOTS program,
shortage of trained personnel, and low sensitivity of smear
microscopy.
Table 1 – Case notification rate of all forms of tuberculosis in the Afar Regional State from 2003 to 2012.
Y Smear-positive PTB Smear-negative PTB EPTB Grand total
No. (%) No. (%) No. (%) No. CDR
2003 266 (18.3) 761 (52.2) 430 (29.5) 1457 18.3
2004 1624 (26.9) 2239 (37.0) 2186 (36.1) 6049 26.9
2005 1269 (32.3) 1745 (44.4) 918 (23.3) 3932 32.3
2006 1173 (36.3) 1243 (38.5) 816 (25.2) 3232 36.3
2007 1454 (38.6) 1380 (36.7) 931 (24.7) 3765 38.6
2008 1542 (39.0) 1376 (34.8) 1041 (26.3) 3959 39.0
2009 1471 (38.0) 1359 (35.1) 1040 (26.9) 3870 38.0
2010 761 (29.7) 1007 (39.3) 793 (31.0) 2561 29.7
2011 398 (26.8) 566 (38.1) 361 (24.3) 927 26.8
2012 1371 (37.2) 1422 (38.9) 892 (24.4) 3685 37.2
Total 11,595 (33.2) 13,859 (39.7) 9838 (28.2) 34,894 33.2












Fig. 1 – Trend of case finding for all forms of tuberculosis
cases in the Afar Regional State from 2003 to 2012. Note:
EPTB = extrapulmonary tuberculosis; PTB = pulmonary
tuberculosis; Y = years; +ve = positive; ve = negative.
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for smear-positive TB among the age group of 25–34 years fol-
lowed by 1245 (6.7%) in the age group of 15–24 years. This indi-
cates that a high proportion of smear-positive TB is available
in those age groups who are the economically productive seg-
ment of the population. This might be due to the fact that69 85




























Fig. 2 – Number of smear-positive retreatment case findings ofthese age groups are active physiologically, socially, behav-
iorally, and biologically and may interact with other infec-
tious individuals, thereby enhancing the chance for
acquiring TB compared with the other age groups. Besides,
there is an agreement in findings that these age groups are
sexually active and the possibility of being infected with
HIV is higher which fuels the susceptibility of TB infection
[13]. The highest numbers of smear-positive TB cases among
similar age groups were also observed by previous studies
[14,15].
The study showed that the average value of TSR (86.5%)
was higher than the average of 72% of other African coun-
tries [16] and slightly higher than the 85% WHO target and
the national average of 84% [12]. TSR was lower than the
85% WHO target from the years 2003 to 2005 and higher
than the WHO target from 2006 to 2011. The lower TSR in
the earlier years might be related to the poor observation
of patients during the course of treatment, poor patient
treatment compliance, poor standardized and improper
recording and reporting systems, inadequate treatment reg-
imens, and an increase in the incidence of drug-resistant
strains. Similar trends in TSR were reported by Woldey-
ohannes et al. [10] in the Gambella region. The possible
explanations for the increase in TSR (>85%) from 2006 to
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Fig. 3 – Trends of case detection rate (CDR) and treatment success rate (TSR) of smear-positive pulmonary tuberculosis in the
Afar Regional State from 2002 to 2011. Note: mov. avg. = moving average; Y = years.
Table 3 – Treatment outcomes of smear-positive pulmonary tuberculosis cases in the Afar Regional State from 2002 to 2011.
Y Cohort cases (N) Evaluated Cured Treatment
completed
Died Failure Defaulted Transfer out Treat
success
TSR
2002 266 266 (100) 65 (24.4) 150 (56.4) 7 (2.6) 12 (4.5) 31 (11.7) 0 215 80.8
2003 1624 1624 (100) 380 (23.4) 927 (57.1) 41 (2.5) 64 (3.9) 119 (3.9) 81 (5.0) 1307 80.5
2004 1269 1269 (100) 543 (42.8) 247 (19.5) 27 (2.1) 16 (1.3) 16 (1.3) 21 (1.7) 790 62.3
2005 1154 1154 (100) 300 (26.0) 619 (53.7) 64 (5.6) 43 (3.7) 0 128 (11.1) 919 79.6
2006 1176 1173 (99.7) 576 (49.0) 539 (46.0) 27 (2.3) 8 (0.7) 14 (1.2) 12 (1.0) 1115 94.8
2007 1454 1454 (100) 756 (52.0) 647 (44.5) 19 (1.3) 4 (0.3) 15 1.0) 14 (1.0) 1403 96.5
2008 1542 1542 (100) 573 (39.4) 843 (54.7) 14 (0.9) 65 (4.3) 59 (3.8) 31 (2.0) 1416 91.8
2009 1471 1471 (100) 439 (29.8) 915 (62.2) 29 (2.0) 22 (1.5) 59 (4.0) 37 (2.5) 1354 92.0
2010 838 256 (30.5) 70 (27.3) 162 (19.3) 6 (0.7) 3 (0.4) 11 (1.3) 4 (0.5) 232 90.6
2011 1371 1371 (100) 543 (39.6) 732 (53.4) 38 (2.8) 96 (7.0) 32 (2.3) 55 (4.0) 1275 93.0
Total 12162 11,583 (95.2) 4245 (34.9) 5781 (47.5) 272 (2.2) 330 (2.7) 353 (2.9) 383 (3.1) 10,091 86.2
Note: TSR = treatment success rate; y = year.
Table 2 – Smear-positive pulmonary tuberculosis cases by sex and age groups in the Afar Regional State from 2005 to 2010.
Sex Total
Male (%) Female (%) No. (%)
Age (y) 0–14 313 1.7 231 1.3 544 3.0
15–24 650 3.5 595 3.2 1245 6.7
25–34 1162 6.3 1148 6.3 2310 12.6
35–44 959 5.2 797 4.4 648 9.6
45–54 340 1.9 308 1.7 956 3.6
55–64 136 0.7 93 0.5 229 1.2
65+ 44 0.2 25 0.1 69 0.3
Total 3917 19.7 3428 17.5 7345 37.2
Note: y = years.
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ensure comprehensive TB control activities in the region
[17].
The average treatment failure rate was about 2.7% for
smear-positive TB cases who were treated with the DOTS pro-
gram for the same study period. The result is higher than a
previous report (0.3%) from the Gambella Region [9]. The cur-
rent 2.7% failure rate might be related to the gradual increas-
ing rate of MDR-TB in the country [5].Limitations of the study
As the data sources were secondary, the existence of poor
records and reporting at each level of the health systemmight
have its own effect in the findings and conclusions of the
study. Furthermore, in this study we could not include data
before the implementation of the DOTS strategy, which might
have supported our study results by clearly indicating the
before and after type of analysis.
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The implementation for the DOTS strategy in the area
improved the CDR of smear-positive TB, although it is unac-
ceptably lower than the recommended WHO target of 70%.
Additionally, the WHO target of 85% for TSR had already been
achieved in the region. However, continued efforts should be
in place to increase the CDR and maintain the high TSR
registered.
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